Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov;136(5):800-804.
doi: 10.1111/bju.16872. Epub 2025 Jul 24.

Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer

Jonathon Carll  1   2   3 , Weiwei Shi  2 , Marlon Perera  1   4   5   6 , Nathan Lawrentschuk  1   2   3   4   5 , Thilakavathi Chengodu  1   3 , Dixon Woon  1   4   6
Affiliations
Review

Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer

Jonathon Carll et al. BJU Int. 2025 Nov.

Abstract

Objective: To provide a comprehensive review and analysis of guidelines from various professional and medical organisations regarding the use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) as a staging scan for men with newly diagnosed intermediate-risk prostate cancer (PCa).

Materials and methods: English-language guidelines and recommendations from the following associations and societies were reviewed and critically analysed: European Association of Urology (EAU), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), Canadian Urological Association (CUA), American Society for Clinical Oncology (ASCO), Society for Nuclear Medicine and Medical Imaging (SNMMI).

Results: There is significant disagreement among guidelines regarding whether PSMA PET is a useful staging tool for men with a new diagnosis of intermediate-risk PCa. There is a stronger consensus that PSMA PET is useful in staging high-risk PCa.

Conclusion: Whilst there is a growing body of evidence that supports the use of PSMA PET in newly diagnosed PCa, there is significant disagreement regarding its use for men with intermediate-risk disease. Recommendations are generally weak and based on expert opinions. This is an area of considerable ongoing research, and guidelines are likely to change as new evidence emerges.

Keywords: Guidelines; Intermediate‐Risk; PSMA PET; Prostate Cancer; Staging.

PubMed Disclaimer

References

    1. Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate‐specific membrane antigen PET‐CT in patients with high‐risk prostate cancer before curative‐intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208–1216 - PubMed
    1. Mazzone E, Cannoletta D, Quarta L et al. A comprehensive systematic review and meta‐analysis of the role of prostate‐specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol 2025; 87: 654–671 - PubMed
    1. Holzgreve A, Unterrainer M, Calais J et al. Is PSMA PET/CT cost‐effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging 2023; 50: 3750–3754 - PMC - PubMed
    1. de Feria Cardet RE, Hofman MS, Segard T et al. Is prostate‐specific membrane antigen positron emission tomography/computed tomography imaging cost‐effective in prostate cancer: An analysis informed by the proPSMA trial. Eur Urol 2021; 79: 413–418 - PubMed
    1. Cornford P, van den Bergh RCN, Briers E et al. EAU‐EANM‐ESTRO‐ESUR‐ISUP‐SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands: EAU Guidelines Office, 2024. https://d56bochluxqnz.cloudfront.net/documents/full‐guideline/EAU‐EANM‐E...

MeSH terms